Posted by Michael Wonder on 31 Oct 2025
NICE’s backing of the prostate cancer drug abiraterone could help thousands and save the NHS millions
30 October 2025 - Today we’ve published final draft guidance recommending abiraterone and its generic variants in combination with androgen deprivation therapy and prednisolone or prednisone as an option for adults with newly diagnosed high-risk hormone‑sensitive metastatic prostate cancer.
The decision marks a significant shift from our 2021 guidance, which could not recommend abiraterone because, at the time, it did not represent value for money for the NHS. The availability of lower-cost generic versions prompted a re-evaluation, leading to today's positive recommendation.
